Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Shares Outstanding (Weighted Average): 2009-2024

Historic Shares Outstanding (Weighted Average) for Ligand Pharmaceuticals (LGND) over the last 16 years, with Dec 2024 value amounting to $18.9 million.

  • Ligand Pharmaceuticals' Shares Outstanding (Weighted Average) rose 7.27% to $19.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.6 million, marking a year-over-year increase of 7.27%. This contributed to the annual value of $18.9 million for FY2024, which is 8.37% up from last year.
  • Ligand Pharmaceuticals' Shares Outstanding (Weighted Average) amounted to $18.9 million in FY2024, which was up 8.37% from $17.4 million recorded in FY2023.
  • In the past 5 years, Ligand Pharmaceuticals' Shares Outstanding (Weighted Average) registered a high of $18.9 million during FY2024, and its lowest value of $16.1 million during FY2020.
  • For the 3-year period, Ligand Pharmaceuticals' Shares Outstanding (Weighted Average) averaged around $17.7 million, with its median value being $17.4 million (2023).
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Shares Outstanding (Weighted Average) decreased by 8.38% in 2020, and later increased by 8.37% in 2024.
  • Over the past 5 years, Ligand Pharmaceuticals' Shares Outstanding (Weighted Average) (Yearly) stood at $16.1 million in 2020, then climbed by 3.86% to $16.7 million in 2021, then rose by 1.09% to $16.9 million in 2022, then increased by 3.21% to $17.4 million in 2023, then rose by 8.37% to $18.9 million in 2024.